Drug Watch

Latest News

FDA
New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia

April 1st 2025

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

pills
The Psychiatric Pipeline in Review: Quarter 1, 2025

March 31st 2025

schizophrenia
Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia

March 31st 2025

schizophrenia
Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia

March 31st 2025

ADHD
Phase 3 Trial Success: Solriamfetol for the Treatment of Adults With ADHD

March 25th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.